Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00738920 · ClinicalTrials.gov registry record · NA
Self Administered Cognitive Behavior Therapy for Irritable Bowel Syndrome
A NA study, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- NA
- Development phase
- 436
- Enrollment target
NCT00738920: Completed NA study, sponsored by State University of New York at Buffalo.
NCT00738920 is a NA study that has completed, run by State University of New York at Buffalo. The registered enrollment target is 436 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00738920, a NA study, has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- NA
- Development phase
- 436 participants
- Enrollment target
Study Summary
The primary goal of the proposed trial is to assess the short- and long-term efficacy of cognitive behavior therapy (CBT) for irritable bowel syndrome using two treatment delivery systems (self administered, therapist administered). Secondary aims seek to specify the conditions under which CBT may (or may not) achieve its effects (moderator questions), why and how these effects are achieved (mediator questions) and at what economic cost. Long term project goals are to develop an effective self-administered behavioral treatment program that can enhance the quality of patient care, improve clinical outcomes, and decrease the economic and personal costs of one of the most prevalent and intractable GI disorders.
Primary Outcome
The CGI-I is a single-item, 7-point centered scale that integrates symptom severity and improvement since the start of treatment. Specific IBS-based anchor points were used, as is the convention for multi-symptom disease states. Response range from 1 (very much worse) to 7 (very much improved), with higher scores indicating greater symptom improvement. Participants who respond 6 (much improved) or 7 (very much improved) are classified as treatment responders.
Interventions
- BEHAVIORAL Self Administered Cognitive Behavior Therapy
- BEHAVIORAL Therapist Administered Cognitive Behavior Therapy
- BEHAVIORAL Behavioral Education and Supportive Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 436 participants |
| Start Date | 2010-08 |
| Est. Completion | 2017-08-31 |
| Phase | NA |
What the finished NCT00738920 record still lists
NCT00738920 is an interventional study that assigns participants to a tested intervention. The registered 436 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 3 interventions - of which Self Administered Cognitive Behavior Therapy is the first listed.
NCT00738920 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00738920 about?
NCT00738920 is a clinical study titled "Self Administered Cognitive Behavior Therapy for Irritable Bowel Syndrome". The primary goal of the proposed trial is to assess the short- and long-term efficacy of cognitive behavior therapy (CBT) for irritable bowel syndrome using two treatment delivery systems (self administered, therapist administered). Secondary aims seek to specify the conditions under which CBT may (...
What is the current status of trial NCT00738920?
This trial is currently completed. It is a NA study. The enrollment target is 436 participants. The study started on 2010-08. Estimated completion is 2017-08-31.
What interventions are being tested in trial NCT00738920?
The interventions under investigation include: Self Administered Cognitive Behavior Therapy (BEHAVIORAL), Therapist Administered Cognitive Behavior Therapy (BEHAVIORAL), Behavioral Education and Supportive Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00738920?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00738920's enrollment target sits among peer trials
436 235th of 2000 higher than 1,766 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02622542 · 436 participants · NA
ACute Uncomplicated Type b Aortic Dissection: Endovascular Repair vs. Best Medical Therapy
- NCT05918211 · 436 participants · Phase 3
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
- NCT06966479 · 436 participants · Phase 2
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
- NCT07318493 · 436 participants · NA
Antiseptic-Coated Sutures and Pancreatic Fistula Risk After Pancreatoduodenectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia